Results 191 to 200 of about 137,029 (384)

Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: 12 months results [PDF]

, 2017
Background: Biological agents, such as infliximab, have transformed the outcomes of patients with immune-mediated inflammatory diseases. The advent of biosimilar treatment options such as CT-P13 promises to improve the availability of biological therapy,
Argüelles Arias, Federico, Castro Laria, Luisa, Guerra Veloz, María Fernanda, Maldonado Pérez, Belén, Merino Bohórquez, Vicente, Perea Amarillo, Raúl, Romero Gómez, Manuel, Vilches Arenas, Ángel   +7 more
core  

Infliximab Is the Drug We Have Been Waiting For in Crohnʼs Disease

, 2000
Paul Rutgeerts
openalex   +1 more source

Infliximab for the Treatment of Crohn'S Disease: Review and Indications for Clinical Use in Canada [PDF]

, 2001
Remo Panaccione
openalex   +1 more source

Assessment of PredictSURE IBD Assay in a Multinational Cohort of Patients With Inflammatory Bowel Disease

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background and Aims PredictSURE IBD is a prognostic blood test that classifies newly diagnosed, treatment‐naïve Inflammatory Bowel Disease (IBD) patients into ‘IBDhi’ (high‐risk) or ‘IBDlo’ (low‐risk) groups (risk of future aggressive disease).
Dahham Alsoud, Nurulamin M. Noor, Lea Ann Chen, Vivian Abadom, Simon H. C. Anderson, Lediona Ardolli, Jordan Axelrad, Peter Bossuyt, Kenneth Croitoru, Oriana M. Damas, Lily Deng, Parakkal Deepak, Juan De La Revilla Negro, Shanika de Silva, Marc Ferrante, Karen Hills, Peter M. Irving, James O. Lindsay, Dana J. Lukin, Paul A. Lyons, Eoin F. McKinney, Maria Oliva‐Hemker, Caterina Oneto, Roohi Patel, Miles Parkes, Lieven Pouillon, João Sabino, Lawrence J. Saubermann, Jenny S. Sauk, Sarah Sheibani, Kenneth G. C. Smith, Keith S. Sultan, Tony C. Tham, Sare Verstockt, Raluca Vrabie, Melissa Weidner, Huimin Yu, Bram Verstockt, James C. Lee, Séverine Vermeire   +39 more
wiley   +1 more source

The metabolomics of psoriatic disease. [PDF]

, 2017
Metabolomics is an emerging new "omics" field involving the systematic analysis of the metabolites in a biologic system. These metabolites provide a molecular snapshot of cellular activity and are thus important for understanding the functional changes ...
Afifi, Ladan, Chang, Hsin Wen, Jeon, Caleb, Lee, Kristina, Liao, Wilson, Trivedi, Megha, Yan, Di   +6 more
core  

Infliximab for Crohn's Disease: More Questions than Answers [PDF]

, 2001
Hugh James Freeman
openalex   +1 more source

Fecal Infliximab Loss [PDF]

Gastroenterology, 2015
Glen A. Doherty, David J. Gibson
openaire   +3 more sources

Use of Ultraviolet‐Induced Fluorescence Dermoscopy for the Diagnosis of Vitiligo‐Like Lesions in Patients Receiving Immune Checkpoint Inhibitors Therapy for Advanced Melanoma: Letter to the Editor

JEADV Clinical Practice, EarlyView.
Laura Rackauskaite, Diana C. O. Jimenez, Iris Zalaudek   +2 more
wiley   +1 more source

IBUS‐SAS Is a Highly Accurate Intestinal Ultrasound Score for Predicting Endoscopic Disease Activity in Ulcerative Colitis

United European Gastroenterology Journal, EarlyView.
ABSTRACT Background The international bowel ultrasound group‐segmental activity score (IBUS‐SAS) is a validated tool with high interobserver agreement for accurately detecting disease activity in Crohn's disease (CD). Here, we addressed whether the IBUS‐SAS is also suitable to assess disease activity in ulcerative colitis (UC). Methods The IBUS‐SAS and
Sarah Fischer, David Fischmann, Judith Wilde, Marcel Vetter, Laurin Wolf, Carol Geppert, Raja Atreya, Maximilian Waldner, Deike Strobel, Markus F. Neurath, Sophie Haberkamp, Sebastian Zundler   +11 more
wiley   +1 more source

Successful treatment of therapy-resistant metastatic Crohn's desiase with infliximab [PDF]

, 2004
CASTIGLIONE, FABIANA, COZZOLINO A, INSABATO, LUIGI, LEMBO, GIUSEPPE, PESCE, GIUSEPPE, RISPO A   +5 more
core   +1 more source